Although a number of studies of transgenic animals made with constructs of the amyloid precursor protein (APP), C-terminal 99 or 1 amino acids (C-99,-1), or beta-amyloid protein (A-beta), have been reported, these animals, to date, have not developed the brain abnormalities characteristic of Alzheimer's disease (AD). A difficulty with most of these studies, all of which utilized cDNA constructs, has been the very low levels of expression of the transgene products. Moreover, there are, as of yet, no published studies that describe animals created by introduction into the mouse germline of transgenes with APP mutations linked to early-onset familial AD (FAD) or hereditary cerebral hemorrhage with amyloidosis, Dutch type (HCHWA-D). We have used yeast artificial chromosome (YAC) and embryonic stem (ES) cell technologies to introduce about 450 kilobases of the human APP gene into mice; these transgenic animals express the wild-type transgene at the level of the endogenous APP gene. In this Project, these strategies will be used to produce transgenic animals with APP mutations linked to FAD or to HCHWA-D, chosen because these mutations were chosen because, in humans, they are linked to early-onset illnesses with distinct phenotypes. To delineate the character/evolution of the pathology, we will examine controls and lines of transgenic mice with a variety of approaches to identify preamyloid deposits, plaques, congophilic angiopathy, abnormalities of the neuronal cytoskeleton, alterations in neural circuits, and synaptic pathology. We will focus on the early stages of A-beta formation, the cells participating in these processes, and using stereological methods, the possibility that animals will show age-related reductions in the numbers of synapses in hippocampus and cortex. Using invasive methods, APP will be radiolabeled by injecting [35S] methionine into the entorhinal cortex, and the transport and processing of APP will be examined in the perforant pathway. Transgenic animals developing brain abnormalities will be extraordinarily valuable for investigations designed to test diagnostic and therapeutic strategies relevant to FAD, HCHWA-D, or AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
2P50AG005146-12
Application #
3745785
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Hadjichrysanthou, Christoforos; McRae-McKee, Kevin; Evans, Stephanie et al. (2018) Potential Factors Associated with Cognitive Improvement of Individuals Diagnosed with Mild Cognitive Impairment or Dementia in Longitudinal Studies. J Alzheimers Dis 66:587-600
Kim, Jeongyong; Bandeen-Roche, Karen (2018) Parametric estimation of association in bivariate failure-time data subject to competing risks: sensitivity to underlying assumptions. Lifetime Data Anal :
Bilgel, Murat; An, Yang; Helphrey, Jessica et al. (2018) Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults. Brain :
Pettigrew, Corinne; Shao, Yi; Zhu, Yuxin et al. (2018) Self-reported Lifestyle Activities in Relation to Longitudinal Cognitive Trajectories. Alzheimer Dis Assoc Disord :
Yasar, Sevil; Varma, Vijay R; Harris, Gregory C et al. (2018) Associations of Angiotensin Converting Enzyme-1 and Angiotensin II Blood Levels and Cognitive Function. J Alzheimers Dis 63:655-664
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Habes, Mohamad; Sotiras, Aristeidis; Erus, Guray et al. (2018) White matter lesions: Spatial heterogeneity, links to risk factors, cognition, genetics, and atrophy. Neurology 91:e964-e975
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Behrens, Stephanie; Rattinger, Gail B; Schwartz, Sarah et al. (2018) Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care. Int Psychogeriatr 30:1499-1507
Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71

Showing the most recent 10 out of 830 publications